IMMUNITYBIO, INC. Shareholders' Equity
IMMUNITYBIO, INC. (IBRX) had Shareholders' Equity of -$1.05 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent -$1.05B.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$870.01M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$500.47M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$524.32M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$1.05B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$870.01M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$500.47M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$524.32M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$570.75M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$591.43M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$489.10M 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$745.15M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$698.39M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$692.01M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$586.99M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$411.72M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$642.12M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$528.98M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$447.33M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$426.70M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$419.81M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$335.64M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$242.17M 10-K · filed 2023-03-01 | |
| 2021-09-30 | -$188.50M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$157.94M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$185.79M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$119.81M 10-K · filed 2022-03-01 | $117.39M 10-K · filed 2021-03-04 |
| 2020-09-30 | $148.62M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $169.65M 10-Q · filed 2020-11-09 | |
| 2020-03-31 | $102.59M 10-Q · filed 2020-08-07 | |
| 2019-12-31 | $16.33M 8-K/A · filed 2021-04-22 | $120.68M 10-K · filed 2020-03-25 |
| 2019-09-30 | $135.96M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $151.27M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $167.81M 10-Q · filed 2020-08-07 | |
| 2018-12-31 | $81.94M 8-K/A · filed 2021-04-22 | $146.01M 10-K · filed 2019-03-13 |
| 2018-09-30 | $162.09M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $181.63M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $200.36M 10-Q · filed 2019-08-06 | |
| 2017-12-31 | $218.84M 10-K · filed 2021-03-04 | |
| 2017-09-30 | $237.70M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $252.92M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $278.37M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $293.42M 10-K · filed 2020-03-25 | |
| 2016-09-30 | $310.89M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $327.36M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $344.50M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $356.00M 10-K · filed 2019-03-13 | |
| 2015-09-30 | $362.93M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $126.52M 10-Q · filed 2015-09-10 | |
| 2014-12-31 | $57.59M 10-K · filed 2018-03-12 | $58.42M 10-Q · filed 2015-09-10 |
| 2013-12-31 | -$3.75M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |